QTTB SEC Filings: 8-K, 10-Q, S-3 & 424B – Q32 Bio

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 5, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 10, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 13, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Q32 Bio Reports Third Quarter 2026 Financial Results and Corporate Updates

Nov 4, 2026

8-K

Q32 Bio Presents Positive Part B Results from SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at EADV Congress 2026

Sep 30, 2026

8-K

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer

Sep 14, 2026

8-K

Q32 Bio Reports Second Quarter 2026 Financial Results and Corporate Update

Aug 5, 2026

8-K

Q32 Bio Inc. Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Jul 15, 2026

8-K

Q32 Bio Announces 36-Week Topline Results for SIGNAL-AA Phase 2a Clinical Trial of Bempikibart

Jul 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jul 28, 2026

424B5

REGISTERED OFFERING

Jul 15, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $200,000,000 | Bank: Morgan Stanley

Jul 13, 2026

424B5

[No Baby Shelf]* April 2026 ATM | Offering amount: $75,000,000 | Bank: Cantor Fitzgerald & Co.

Apr 24, 2026

424B5

March 2026 ATM | Offering amount: $14,200,000 | Bank: Cantor Fitzgerald & Co.

Mar 27, 2026

424B5

REGISTERED OFFERING

Feb 17, 2026

Registrations

TYPE

HEADLINE

FILED AT

S-3

SHARE RESALE REGISTRATION

Jul 17, 2026

S-3

June 2026 SHELF

Jun 25, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 10, 2026

POS AM

Form POS AM - Post-Effective amendments for registration statement

Apr 11, 2025

S-3

April 2025 SHELF

Apr 11, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 30, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 30, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 11, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2023

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

Boxer Capital Management, LLC (Filed by)

Nov 6, 2026

SCHEDULE 13G/A

Opaleye Management Inc. (Filed by)

Nov 6, 2026

SCHEDULE 13G

BANK OF AMERICA CORP /DE/ (Filed by)

Oct 28, 2026

Morrison Jodie Pope (Reporting)

Oct 14, 2026

Violette Shelia M. (Reporting)

Oct 14, 2026

Kalowski Lee (Reporting)

Oct 14, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 29, 2026

EFFECT

Form EFFECT - Notice of Effectiveness

Jul 14, 2026

LETTER

Form UPLOAD - SEC-generated letter

Aug 28, 2025

CORRESP

Form CORRESP - Correspondence

Aug 26, 2025

CORRESP

Form CORRESP - Correspondence

Jul 31, 2025

LETTER

Form UPLOAD - SEC-generated letter

Jul 30, 2025

Q32 Bio Inc. QTTB · SEC Filings